Sutro Biopharma, Inc. (STRO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 43 | 62 | 68 | 154 | 62 | 102 | 46 | 50 |
| Operating profit | $m | -105 | -142 | ||||||
| Net profit | $m | -32 | -106 | -119 | -107 | -227 | -191 | -181 | -68 |
| EPS reported | $ | -22.49 | -17.42 | ||||||
| Operating cashflow per share | $ | -20.86 | -11.59 | ||||||
| Capex per share | $ | 0.20 | 0.04 | ||||||
| FCF per share | $ | -21.06 | -11.63 | ||||||
| Free cash flow | $m | -179 | -146 | ||||||
| Net debt | $m | -141 | -164 | ||||||
| Book value equity | $m | -132 | -103 | ||||||
| Book value per share | $ | -15.59 | -6.23 | ||||||
| Number of shares | m | 8.5 | 16.57 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.74 | -0.95 | ||||||
| P/S LTM | x | 0.96 | 2.15 | ||||||
| P/FCF LTM | x | -0.55 | -0.68 | ||||||
| EV/EBITDA LTM | x | -0.38 | -0.42 | ||||||
| EV/Sales LTM | x | 0.55 | 1.88 | ||||||
| Earnings Yield LTM | % | -1.94% | -46.03% | ||||||
| FCF Yield | % | -181.98% | -148.11% | ||||||
| Quality | |||||||||
| ROE | % | +144.27% | +192.77% | ||||||
| ROIC | % | -98.52% | -64.32% | ||||||
| Operating margin | % | -1.02% | -1.16% | ||||||
| Gross margin | % | +92.85% | +98.72% | ||||||
| FCF/Sales | % | -174.59% | -152.74% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +65.18% | -26.34% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -11.42 | -13.50 | ||||||
| Net Debt/EBITDA | x | 0.29 | 0.57 | ||||||
| EBIT/Net interest | x | -2.75 | -2.89 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | 1.07 | 1.59 | ||||||
| Gross debt/equity | x | -0.12 | -0.10 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free